2023 年全年,得益于美国 PPU 业务的强劲销量增长以及许可销售的大幅贡献,集团总销售额增长 42% 至 1050 万欧元。集团 2023 年的营业收入显着提高至 120 万欧元(而 2022 年的亏损为 -910 万欧元),反映了集团与天士力合资公司的战略合作伙伴关系的积极影响。截至 2023 年 12 月 31 日,现金和现金等价物为 800 万欧元,自 2022 年 12 月 31 日以来增加 480 万欧元,这主要是由于为 Telix Pharmaceuticals 预留的增资。2024 年第一季度,占美国销售额 50% 的按次付费 (PPU) 业务继续追踪 2023 年观察到的有利利用趋势,销量同比增长 47%。谈到业绩,Mauna Kea Technologies 董事长兼首席执行官 Sacha Loiseau 博士表示:“2023 年标志着公司密集转型期的结束。该转型期始于 2021 年底,重点是建立战略合作伙伴关系并增强我们在美国的业务发展势头和生产力。我对我们在履行承诺方面取得的进展感到非常高兴,这些承诺包括一方面与中国天士力建立战略合作伙伴关系,扩大与 Telix 在泌尿肿瘤学领域的合作——后者现在是我们的最大股东;另一方面,运营卓越,美国 Cellvizio 手术数量持续增加,超过了每季度 1,000 例的重要里程碑,同时经营亏损显着减少,资产负债表得到加强。”
The 2024 Corporate Day event (the “ Event ”) of AIM Vaccine Co., Ltd. (“ AIM Vaccine ” or the “ Group ”) was successfully held on November 21, 2024. The theme of the Event is “Persisting in Forging Honor, Leading Innovation with Action”. 57 securities firms and institutional investors, including CITIC Securities ( 中信证券), Guotai Junan ( 国泰君安), Shenwan Hongyuan ( 申万宏源), Huaxin Securities ( 华鑫证券), Guosheng Securities ( 国盛证券), Everbright Securities ( 光大证券), China Merchants Capital ( 招商局资本), Chengtong Fund ( 诚通基金), Wisdomshire Asset Management ( 睿郡资产), and Tasly Capital ( 天士力资本), as well as some industry experts, were invited to the Event. The attendees visited the modern production base of the Group, learned about the production process, and exchanged ideas with senior management of the Group on the blockbuster large single product vaccines that the Group has applied for launch, as well as our product pipeline layout, product export strategy, and future development plans. The agenda of the Event is as follows: